{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:29:33Z","timestamp":1781522973746,"version":"3.54.1"},"reference-count":34,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University","award":["R016533011"],"award-info":[{"award-number":["R016533011"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate disease flares and associated factors, as well as the Coronavirus disease 2019 (COVID-19) among adolescents with systemic lupus erythematosus (SLE) after receiving COVID-19 vaccination. Additionally, it sought to determine any difference in year-on-year flare rates before and after vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a 12-month prospective study in adolescent SLE (adoSLE) patients aged 12\u201318\u00a0years who had no prior history of COVID-19 and received a 2-dose BNT162b2 mRNA COVID-19 vaccine. A booster dose was administered 4\u20136\u00a0months later, depending on vaccine availability and patient acceptance. Clinical characteristics, the safety of estrogens in lupus erythematosus national assessment-SLE disease activity index (SELENA-SLEDAI) flare index, and renal flare were evaluated and contrasted against pre-vaccination data. COVID-19 during follow-up were noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-nine vaccinated adoSLE patients, with the mean age of 15.8 \u00b1 1.6\u00a0years and female predominant (92.8%), were included. Forty-six (66.7%) patients received a booster dose at 4-6\u00a0months after primary series. Compared between pre- and post- COVID-19 vaccination, year-on-year flare rates remained consistent [20 (29.0%) versus 24 (34.8%),\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .371]. Non-use of hydroxychloroquine (adjusted odds ratio [aOR] 18.83, 95% CI: 1.97, 179.60,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .011) and a SELENA-SLEDAI score \u22658 within 12\u00a0months prior to vaccination (aOR 5.33, 95% CI: 1.38, 20.55,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .015) were independent factors of disease flares. An increment in post-vaccine renal flare rate was observed [6 (8.7%) versus 14 (20.3%),\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .046]. Among 14 adoSLE patients with renal flare, 13 (92.9%) patients had previous lupus nephritis, and new-onset proteinuria or increased proteinuria (71.4%) was the most common finding. Thirty-four (49.3%) patients contracted COVID-19 within a year post-vaccination, all presenting with mild to moderate symptoms; among the 46 patients who received a booter, 15 (32.6%) experienced COVID-19.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>COVID-19 vaccination is effective and safe in preventing severe COVID-19 among adoSLE patients, without increasing annual SLE flare rates. However, close monitoring for renal flares is recommended, particularly for patients with a history of LN. Although vaccinated adoSLE patients contracted COVID-19, their outcomes were favorable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09612033251331244","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T18:21:08Z","timestamp":1743272468000},"page":"562-570","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Disease exacerbation and COVID-19 following mRNA COVID-19 vaccination in adolescents with Systemic Lupus Erythematosus"],"prefix":"10.1177","volume":"34","author":[{"given":"Sutheera","family":"Thepveera","sequence":"first","affiliation":[{"name":"Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirirat","family":"Charuvanij","sequence":"additional","affiliation":[{"name":"Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3879-4374","authenticated-orcid":false,"given":"Maynart","family":"Sukharomana","sequence":"additional","affiliation":[{"name":"Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanarin","family":"Thunsiribuddhichai","sequence":"additional","affiliation":[{"name":"Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kraisoon","family":"Lomjansook","sequence":"additional","affiliation":[{"name":"Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanaporn","family":"Chaiyapak","sequence":"additional","affiliation":[{"name":"Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirut","family":"Pattaragarn","sequence":"additional","affiliation":[{"name":"Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achra","family":"Sumboonnanoda","sequence":"additional","affiliation":[{"name":"Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-2245","authenticated-orcid":false,"given":"Nuntawan","family":"Piyaphanee","sequence":"additional","affiliation":[{"name":"Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-022-01047-2"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221636"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218946"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01046-2"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222550"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00190-4"},{"issue":"5","key":"e_1_3_6_8_2","first-page":"2143","article-title":"Inflammatory rheumatic diseases developed after COVID-19 vaccination: presentation of a case series and review of the literature","volume":"27","author":"Akkuzu G","year":"2023","unstructured":"Akkuzu G, Bes C, \u00d6zg\u00fcr DS, et al. Inflammatory rheumatic diseases developed after COVID-19 vaccination: presentation of a case series and review of the literature. Eur Rev Med Pharmacol Sci 2023; 27(5): 2143\u20132151.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-022-00313-8"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.01.013"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.07.019"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac604"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05980-5"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41937"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.08.068"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead047"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-00985-0"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108907"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06186-z"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06067-5"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac103"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac105"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241232576"},{"key":"e_1_3_6_24_2","volume-title":"COVID-19 vaccines for people who are moderately or severely immunocompromised","author":"Centers for Disease Control and Prevention","year":"2024","unstructured":"Centers for Disease Control and Prevention. COVID-19 vaccines for people who are moderately or severely immunocompromised. [Internet], 2024. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html."},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.42372"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2022030258"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033231164262"},{"issue":"3","key":"e_1_3_6_32_2","first-page":"676","article-title":"Immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus: results from the prospective cohort study COVAC-SLE","volume":"41","author":"Larsen ES","year":"2023","unstructured":"Larsen ES, Nilsson AC, M\u00f6ller S, et al. Immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus: results from the prospective cohort study COVAC-SLE. Clin Exp Rheumatol 2023; 41(3): 676\u2013684.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"e_1_3_6_33_2","first-page":"856","article-title":"Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study","volume":"30","author":"Zen M","year":"2012","unstructured":"Zen M, Bassi N, Nalotto L, et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol 2012; 30(6): 856\u2013863.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3842-z"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00722-z"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251331244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033251331244","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251331244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:28:51Z","timestamp":1777678131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033251331244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/09612033251331244"],"URL":"https:\/\/doi.org\/10.1177\/09612033251331244","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]}}}